SCNI (Scinai Immunotherapeutics) Short-Term Debt to Capital

Scinai Immunotherapeutics (SCNI) develops universal vaccines and immunotherapy methods, ensuring rapid sales growth with minimal unit costs. The business relies on the development of anti-inflammatory nanoantibodies, protecting its position through patents and strict regulatory control. The company is also competing for leadership in the treatment of autoimmune pathologies, outpacing industry behemoths. The indicator stands at 0.02, and the asset's price chart is provided below.

Professional selection of resilient assets requires liquidity analysis by comparing short-term liabilities to equity, where the short-term debt-to-equity ratio reflects the risk of funding shortages for operational activities. For Scinai Immunotherapeutics (SCNI), low values for this metric confirm financial autonomy, which is supported by the company's own GMP production facility that minimizes costs associated with third-party drug manufacturing.